Format

Send to

Choose Destination
Future Med Chem. 2012 Sep;4(13):1671-9. doi: 10.4155/fmc.12.134.

Small-molecule Klotho enhancers as novel treatment of neurodegeneration.

Author information

1
Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA. cabraham@bu.edu

Abstract

The majority of neurodegenerative diseases have an important age component, and thus, understanding the molecular changes that occur during normal aging of the brain is of utmost relevance. In search for the basis of the age-related cognitive decline found in humans, monkeys and rodents, we study the rhesus monkey. Surprisingly, there is no loss of neurons in aged monkey brains. However, we reported white matter and myelin abnormalities in aged monkeys, similar to those observed in Alzheimer's disease and multiple sclerosis patients. In a microarray analysis comparing young and old monkey white matter, we discovered that Klotho is downregulated in the aged brain. We then asked whether there is a connection between the age-related cognitive decline, myelin abnormalities and Klotho downregulation. If such a connection is found, compounds that upregulate Klotho expression could become of therapeutic interest for the treatment of multiple sclerosis, and perhaps even Alzheimer's disease.

PMID:
22924505
PMCID:
PMC3564652
DOI:
10.4155/fmc.12.134
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center